CN109071563A - 布鲁顿氏酪氨酸激酶的抑制剂及其使用方法 - Google Patents

布鲁顿氏酪氨酸激酶的抑制剂及其使用方法 Download PDF

Info

Publication number
CN109071563A
CN109071563A CN201680072147.9A CN201680072147A CN109071563A CN 109071563 A CN109071563 A CN 109071563A CN 201680072147 A CN201680072147 A CN 201680072147A CN 109071563 A CN109071563 A CN 109071563A
Authority
CN
China
Prior art keywords
base
oxo
carboxylic acid
acid amides
thia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680072147.9A
Other languages
English (en)
Chinese (zh)
Inventor
N.阿罗拉
G.M.巴卡尼
J.K.巴尔贝
S.D.本贝内克
M.蔡
W.陈
C.P.德克胡特
J.P.爱德华兹
B.戈什
B.郝
K.克罗伊特
G.李
M.S.蒂切诺尔
J.D.韦纳布莱
J.韦
J.J.M.韦纳
Y.吴
Y.朱
F.张
Z.张
K.肖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to CN202110404344.9A priority Critical patent/CN113105475B/zh
Publication of CN109071563A publication Critical patent/CN109071563A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201680072147.9A 2015-12-10 2016-12-09 布鲁顿氏酪氨酸激酶的抑制剂及其使用方法 Pending CN109071563A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110404344.9A CN113105475B (zh) 2015-12-10 2016-12-09 布鲁顿氏酪氨酸激酶的抑制剂及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562265780P 2015-12-10 2015-12-10
US62/265780 2015-12-10
PCT/US2016/065964 WO2017100668A1 (en) 2015-12-10 2016-12-09 Inhibitors of bruton's tyrosine kinase and methods of their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110404344.9A Division CN113105475B (zh) 2015-12-10 2016-12-09 布鲁顿氏酪氨酸激酶的抑制剂及其使用方法

Publications (1)

Publication Number Publication Date
CN109071563A true CN109071563A (zh) 2018-12-21

Family

ID=57681785

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680072147.9A Pending CN109071563A (zh) 2015-12-10 2016-12-09 布鲁顿氏酪氨酸激酶的抑制剂及其使用方法
CN202110404344.9A Active CN113105475B (zh) 2015-12-10 2016-12-09 布鲁顿氏酪氨酸激酶的抑制剂及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110404344.9A Active CN113105475B (zh) 2015-12-10 2016-12-09 布鲁顿氏酪氨酸激酶的抑制剂及其使用方法

Country Status (16)

Country Link
US (3) US10689396B2 (enrdf_load_stackoverflow)
EP (1) EP3386992B1 (enrdf_load_stackoverflow)
JP (2) JP7110097B2 (enrdf_load_stackoverflow)
KR (1) KR20180094514A (enrdf_load_stackoverflow)
CN (2) CN109071563A (enrdf_load_stackoverflow)
AR (1) AR107041A1 (enrdf_load_stackoverflow)
AU (1) AU2016366546B2 (enrdf_load_stackoverflow)
BR (1) BR112018011525B1 (enrdf_load_stackoverflow)
CA (1) CA3007993C (enrdf_load_stackoverflow)
EA (1) EA038031B1 (enrdf_load_stackoverflow)
IL (1) IL259862B (enrdf_load_stackoverflow)
JO (1) JO3793B1 (enrdf_load_stackoverflow)
MX (1) MX386700B (enrdf_load_stackoverflow)
TW (1) TWI739779B (enrdf_load_stackoverflow)
UY (1) UY37016A (enrdf_load_stackoverflow)
WO (1) WO2017100668A1 (enrdf_load_stackoverflow)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110028525A (zh) * 2018-04-13 2019-07-19 太仓运通新材料科技有限公司 一种2-氟磷酰基乙酸三乙酯的合成方法
CN111635368A (zh) * 2020-06-12 2020-09-08 东莞市东阳光仿制药研发有限公司 一种胺化合物的制备方法
CN114401957A (zh) * 2019-09-04 2022-04-26 正大天晴药业集团股份有限公司 一种喹唑啉衍生物的制备方法及其结晶
CN114478346A (zh) * 2021-12-31 2022-05-13 和鼎（南京）医药技术有限公司 一种制备乌帕替尼中间体的方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3003987B2 (ja) 1996-08-20 2000-01-31 篠▲崎▼ 晴彦 合成樹脂管内に施設されるケーブルの支持装置及びそのケーブル支持具を取付ける方法
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
EP3596087A1 (en) * 2017-03-15 2020-01-22 Janssen Sciences Ireland Unlimited Company Methods of selective aryl- and heteroaryl-nitrogen bond formation
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物
FI3860989T3 (fi) * 2018-10-05 2023-05-25 Forma Therapeutics Inc Ubikitiinispesifisen proteaasi 30:n (usp30) inhiboiminen
US20230030720A1 (en) 2018-12-06 2023-02-02 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007092879A2 (en) * 2006-02-08 2007-08-16 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
CN101056639A (zh) 2004-09-15 2007-10-17 詹森药业有限公司 噻唑并吡啶激酶抑制剂
WO2006118749A1 (en) * 2005-05-04 2006-11-09 Janssen Pharmaceutica, N.V. Thia-tetraazaacenaphthylene kinase inhibitors
US7605154B2 (en) 2005-08-08 2009-10-20 Janssen Pharmaceutica N.V. Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors
PT2526933E (pt) 2006-09-22 2015-06-23 Pharmacyclics Inc Inibidores da tirosina-quinase de bruton
US8598174B2 (en) 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
WO2011133609A2 (en) 2010-04-19 2011-10-27 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of btk inhibitors
FR2978441A1 (fr) 2011-07-25 2013-02-01 Diverchim Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
EP2970291B1 (en) 2013-03-15 2022-05-11 Janssen Pharmaceutica, N.V. Processes and intermediates for preparing a medicament
MY179781A (en) * 2013-12-11 2020-11-13 Biogen Ma Inc Biaryl inhibitors of bruton's tyrosine kinase
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007092879A2 (en) * 2006-02-08 2007-08-16 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110028525A (zh) * 2018-04-13 2019-07-19 太仓运通新材料科技有限公司 一种2-氟磷酰基乙酸三乙酯的合成方法
CN114401957A (zh) * 2019-09-04 2022-04-26 正大天晴药业集团股份有限公司 一种喹唑啉衍生物的制备方法及其结晶
CN114401957B (zh) * 2019-09-04 2023-11-21 正大天晴药业集团股份有限公司 一种喹唑啉衍生物的制备方法及其结晶
CN111635368A (zh) * 2020-06-12 2020-09-08 东莞市东阳光仿制药研发有限公司 一种胺化合物的制备方法
CN111635368B (zh) * 2020-06-12 2021-06-29 东莞市东阳光仿制药研发有限公司 一种胺化合物的制备方法
CN114478346A (zh) * 2021-12-31 2022-05-13 和鼎（南京）医药技术有限公司 一种制备乌帕替尼中间体的方法

Also Published As

Publication number Publication date
US10689396B2 (en) 2020-06-23
UY37016A (es) 2017-06-30
AR107041A1 (es) 2018-03-14
TW201734020A (zh) 2017-10-01
US10822348B2 (en) 2020-11-03
EA201891379A1 (ru) 2018-12-28
IL259862B (en) 2022-04-01
CA3007993C (en) 2024-01-16
US20190284203A1 (en) 2019-09-19
CN113105475B (zh) 2022-09-09
JP2022141851A (ja) 2022-09-29
AU2016366546B2 (en) 2021-08-12
US20190284204A1 (en) 2019-09-19
JP7471348B2 (ja) 2024-04-19
JP7110097B2 (ja) 2022-08-01
KR20180094514A (ko) 2018-08-23
CA3007993A1 (en) 2017-06-15
EP3386992B1 (en) 2019-11-27
EA038031B1 (ru) 2021-06-25
BR112018011525B1 (pt) 2023-10-24
WO2017100668A1 (en) 2017-06-15
AU2016366546A1 (en) 2018-05-31
MX2018007084A (es) 2018-11-09
CN113105475A (zh) 2021-07-13
TWI739779B (zh) 2021-09-21
BR112018011525A2 (pt) 2018-11-21
JP2018536684A (ja) 2018-12-13
EP3386992A1 (en) 2018-10-17
IL259862A (en) 2018-07-31
JO3793B1 (ar) 2021-01-31
MX386700B (es) 2025-03-19
US10800792B2 (en) 2020-10-13
US20170283431A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
CN109071563A (zh) 布鲁顿氏酪氨酸激酶的抑制剂及其使用方法
CN105916855B (zh) 作为酪蛋白激酶1d/e抑制剂的取代的4，5，6，7-四氢吡唑并[1，5-a]吡嗪衍生物
CN109195965A (zh) Wdr5蛋白质-蛋白质结合的抑制剂
TWI729047B (zh) 布魯頓氏（ｂｒｕｔｏｎ）酪胺酸激酶抑制劑及其使用方法
CN109563043A (zh) 作为dnmt1的抑制剂的取代的吡啶
CN108093636A (zh) 用于治疗癌症的吲哚胺2,3-双加氧酶抑制剂
CN105658653A (zh) 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
CN109641906A (zh) 杂芳基取代的氨基吡啶化合物
CN116783199A (zh) 作为btk抑制剂的吡唑并[1,5-a]吡嗪衍生物
CN113563311A (zh) 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物
WO2018103058A1 (en) Inhibitors of bruton's tyrosine kinase and methods of their use
HK40062758A (en) Diarylthiohydantoin compound as androgen receptor antagonist
HK40052204A (en) Polycyclic compounds as inhibitors of bruton's tyrosine kinase
HK40052204B (en) Polycyclic compounds as inhibitors of bruton's tyrosine kinase
HK40019862A (en) Diarylthiohydantoin compound as androgen receptor antagonist
HK40019862B (en) Diarylthiohydantoin compound as androgen receptor antagonist
HK40048952A (en) Heterocyclic compound, intermediate, preparation method therefor and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181221

WD01 Invention patent application deemed withdrawn after publication